Condition: Adrenal Cortical Carcinoma · Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
This clinical trial is a single-arm, non-randomized, prospective phase II study. The study aims to evaluate if the maintenance immunotherapy with cemiplimab in patients with AdrenoCortical Carcinoma (ACC), who obtained disease response or stabilization after first-line chemotherapy, may delay/prevent disease progression. The study will be conducted at ASST Spedali Civili Hospital, Brescia - Italy.
This description comes directly from the study's public registry record.
Aldo Roccaro, MD, PhD · 00390303996851 · clinicaltrialcenter@asst-spedalicivili.it
Always discuss trial participation with your own doctor first.
| S.C. Oncologia - ASST Spedali Civili di Brescia | Brescia, Brescia, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07085572